Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Globalization and Health
Published in: Globalization and Health 1/2014

Open Access 01-12-2014 | Review

The burden and treatment of diabetes in France

Authors: Karine Chevreul, Karen Berg Brigham, Clara Bouché

Published in: Globalization and Health | Issue 1/2014

Login to get access

Abstract

Background

The objective of this review was to describe and situate the burden and treatment of diabetes within the broader context of the French health care system.

Methods

Literature review on the burden, treatment and outcomes of diabetes in France, complemented by personal communication with with diabetes experts in the Paris public hospital system.

Results

Prevalence of diabetes in the French population is estimated at 6%. Diabetes has the highest prevalence among all chronic conditions covered 100% by France’s statutory health insurance (SHI), and the number of covered patients has doubled in the past 10 years. In 2010, the SHI cost for pharmacologically-treated diabetes patients amounted to €17.7 billion, including an estimated €2.5 billion directly related to diabetes treatment and prevention and €4.2 billion for treatment of diabetes-related complications. In 2007, the average annual SHI cost was €6 930 for patients with type 1 diabetes and €4 890 for patients with type 2 diabetes. Complications are associated with significantly increased costs. Diabetes is a leading cause of adult blindness, amputation and dialysis in France, which also has one of the highest rates of end-stage renal disease in Europe. Cardiovascular disease is the leading cause of death among people with diabetes. Historically, the French health care system has been more oriented to curative acute care rather than preventive medicine and management of long-term chronic diseases. More recently, the government has focused on primary prevention as part of its national nutrition and health program, with the goal of reducing overweight and obesity in adults and children. It has also recognized the critical role of the patient in managing chronic diseases such as diabetes and has put into place a free patient support program called “sophia”. Additional initiatives focus on therapeutic patient education (TPE) and the development of personalized patient pathways.

Conclusions

While France has been successful in protecting patients from the financial consequences of diabetes through its SHI coverage, improvements are necessary in the areas of prevention, monitoring and reducing the incidence of complications. Systemic changes must be made to improve the coordination and delivery of chronic care.
Literature
1.
Chevreul K, Durand-Zaleski I, Bahrami S, Hernandez-Quevedo C, Mladovsky P: France: Health system review. Health Syst Transit. 2010, 12 (6): 1-291.PubMed
2.
3.
4.
5.
Ricci P, Blotière PO, Weill A, Simon D, Tuppin P, Ricordeau P, Allemand H: Diabète traité: quelles évolutions entre 2000 et 2009 en France?. Bull Epidémiol Hebd. 2010, 42–43: 425-431.
6.
7.
Bonaldi C, Vernay M, Roudier C, Salanave B, Castetbon K, Fagot-Campagna A: Prévalence du diabète chez les adultes âgeés de 18 à 74 ans résident en France métropolitaine. Etude national nutrition santé, 2006–2007. Diabetes Metab. 2009, 35: A18-CrossRef
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Robert J, Roudier C, Poutignat N, Fagot-Campagna A, Weill A, Rudnichi A, Thammavong N, Fontbonne A, Detournay B, : Prise en charge des personnes diabétiques de type 2 en France en 2007 et tendances par rapport à 2001. Bull Epidemiol Hebd. 2009, 42–43: 455-460.
21.
22.
23.
Hirtzlin I, Fagot-Campagna A, Girard-Le Gallo I, Vallier N, Poutignat N, Weill A, Le Laidier S: Dépistage du diabète : les données de l’Echantillon Permanent des Assurés Sociaux, 2000–2001. Rev Epidemiol Santé Publique. 2004, 52: 110-126.
24.
25.
Chambonnet JY, Mimault C: Diabète de type 2: quelles connaissances des recommandations?. Rev Prat Med Gen. 2004, 18: 1195-1199.
26.
Cogneau J, Lehr-Drylwicz AM, Bachimont J, Letoumy A: Ecarts entre le referential et la pratique dans le diabète de type 2. La presse médicale. 2007, 36: 164-170.CrossRef
27.
28.
29.
30.
Deb N, Thuret G, Estour B, Massin P, Gain P: Screening for diabetic retinopathy in France. Diabetes Metab. 2004, 30: 140-145.PubMedCrossRef
31.
Delcourt C, Massin P, Rosilio M: Epidemiology of diabetic retinopathy: Expected vs reported prevalence of cases in the French population. Diabetes Metab. 2009, 35: 431-438.PubMedCrossRef
32.
Massin P, Chabouis A, Erginay A, Viens-Bitker C, Lecleire-Collet A, Meas T, Guillausseau PJ, Choupot G, André B, Denormandie P: OPHDIAT: A telemedical network screening system for diabetic retinopathy in the Ile-de-France. Diabetes Metab. 2008, 34: 227-234.PubMedCrossRef
33.
Soulié-Strougar M, Charles A, Métral P, Querciq P, Souchier M, Chirpaz L, Bron A, Creuzot-Garcher C: Dépistage de la rétinopathie diabétique en Bourgogne par un rétinographe non mydriatique itinérant. J Fr Ophtalmol. 2007, 30: 121-126.PubMedCrossRef
34.
Tadayoni R, Massin P: Dépistage de la rétinopathie diabétique: la rétinographie non mydriatique. Ann Endocrinol. 2003, 64 (Suppl 3): 1S45-1S50.
35.
36.
Fagot-Campagna A, Fosse S, Weill A, Simon D, Varroud-Vial M: Rétinopathie et neuropathie périphérique liées au diabète en France métropolitaine: dépistage, prévalence et prise en charge médicale, étude Entred 2001. Bull Epidemiol Hebd. 2005, 12–13: 48-50.
37.
Fagot-Campagna A, Fosse S, Roudier C, Ramon I, Penfornis A, Lecomte P, Bourdel-Marchasson I, Chantry M, Deligne J, Fournier C, Poutignat N, Weill A, Paumier A, Eschewège E, : Caractéristiques, risque vasculaire et complications chez les personnes diabétiques en France métropolitaine: d’importantes évolutions entre Entred 2001 et Entred 2007. Bull Epidemiol Hebd. 2009, 42–43: 450-455.
38.
Couchoud C, Villar E, Frimat L, Fagot-Campagna A, Stengel B, : L’insuffisance rénale chronique terminale associée à un diabète : fréquence et conditions d’initiation du traitement de suppléance, France, 2006. Bull Epidemiol Hebd. 2008, 43: 414-418.
39.
Ricci P, Chantry M, Detournay B, Poutignat N, Kushik-Joinville O, Raimond V, Thammavong N, Weill A, : Coûts des soins remboursés par l’Assurance maladie aux personnes traits pour diabète: Etudes Entred 2001 et 2007. Bull Epidemiol Hebd. 2009, 42–43: 464-469.
40.
41.
42.
Kusnik-Joinville O, Weill A, Ricci P, Ricordeau P, Allemand H: Motifs et caractéristics des hospitalisations en 2007 des personnes traitées pour diabète en France. Diabetes Metab. 2009, 35 (S1): 18-CrossRef
43.
Ricci P, Weill A, Ricordeau P, Allemand H: Dynamique des dépenses hospitalières des personnes traitées pour diabète, en France (2007–2008). Prat Organ Soins. 2010, 41 (4): 293-301.CrossRef
44.
Colin X, Lafuma A, Gueron B: Costs of cardiovascular events of diabetic patients in the French hospitals. Diabetes Metab. 2007, 33: 310-313.PubMedCrossRef
45.
Ricci P, Chantry M, Detournay B, Poutignat N, Kusnik-Joinville O, Raimond V, Thamavong N, Weill A, : Analyse économique des soins des personnes traitées pour diabète (etudes Entred 2001 et 2007). Prat Organ Soins. 2010, 41: 1-10.CrossRef
46.
Marissal JP, Gueron B, Dervaux B: Prise en compte de l’effet propre du diabète de type II sur la mesure de coût de ses principles complications. Rev Epidemiol Sante Publique. 2006, 54: 137-147.PubMedCrossRef
47.
Marissal JP, Sailly JC, Crainich D, Lebrun T: Evaluation de l’impact budgétaire de l’application des recommandations de bonne pratique dans le diabète de type II en France. Rev Epidemiol Sante Publique. 2005, 53: 1S67-1S78.PubMedCrossRef
48.
Vallier N, Weill A, Salanave B, Bourrel R, Cayla M, Suarez C, Ricordeau P, Allemand H: Coût des trente affections de longue durée pour les bénéficiaires du régime général de l’assurance maladie in 2004. Prat Organ Soins. 2006, 37 (4): 267-283.
49.
Ramon I, Jougla E, Weill A, Eschwège E, Simon D, Fagot-Campagna A: Description de la mortalité et des causes de décès dans une cohort d’adultes diabétiques, en France métropolitaine. Etude Entred 2001. Bull Epidemiol Hebd. 2009, 42–43: 469-472.
50.
Fosse S, Jacqueminet S-A, Duplan H, Hartemann-Heurtier A, Ha Van G, Grimaldi A, Fagot-Campagna A: Incidence et caractéristiques des amputations de membres inférieurs chez les personnes diabétiques en France métropolitaine, 2003. Bull Epidemiol Hebd. 2006, 10: 71-73.
51.
52.
Detournay B, Cros S, Charbonnel B, Grimaldi A, Liard F, Cogneau J, Fagnani F, Eschwège E: Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab. 2000, 26: 43-49.
53.
Malgrange D, Richard JL, Leymarie F: Screening diabetic patients at risk for foot ulceration. A multi-centre hospital-based study in France. Diabetes Metab. 2003, 29: 261-268.PubMedCrossRef
54.
Apelquist J, Bakker K, van Houtum WH, Schaper NC, : Practical guidelines on the management and prevention of the diabetic foot based upon the International Consensus on the Diabetic Foot (2007) prepared by the International Working Group on the Diabetic Foot. Diabetes Metab. 2008, 24 (Suppl 1): S181-S187.CrossRef
55.
Couchoud C, Fagot-Campagna A: Diabète et insuffisance rénale terminale en 2006. Nephrol Ther. 2008, 4: S157-S160.CrossRef
56.
Schoen C, Osborn R, How SKH, Doty MM, Peugh J: In chronic condition: experiences of patients with complex health care needs in eight countries, 2008. Health Aff (Millwood). 2009, 28: w1-w16.CrossRef
Metadata
Title
The burden and treatment of diabetes in France
Authors
Karine Chevreul
Karen Berg Brigham
Clara Bouché
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Globalization and Health / Issue 1/2014
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/1744-8603-10-6

Other articles of this Issue 1/2014

Globalization and Health 1/2014 Go to the issue

Debate

On the margins of aid orthodoxy: the Brazil-Mozambique collaboration to produce essential medicines in Africa

Research

China’s role as a global health donor in Africa: what can we learn from studying under reported resource flows?

Commentary

Hospital accreditation: lessons from low- and middle-income countries

Research

Patient factors to target for elimination of mother-to-child transmission of HIV

Research

Enhancing medicine price transparency through price information mechanisms

Commentary

Open access: academic publishing and its implications for knowledge equity in Kenya